FDA Issues Corrected Advice To InflaRx’s Vilobelimab Study In Skin Disease
InflaRx N.V. (NASDAQ: IFRX) has
See Why Did InflaRx Pause Late-Stage Vilobelimab Trial In Chronic Skin Condition
InflaRx N.V. (NASDAQ: IFRX) has received an advice letter from the FDA about the vilobelimab Phase 3 program for hidradenitis suppurativa (HS), a condition that causes small, painful lumps to form under the skin.
InflaRx Reports Progress In Ongoing Phase II Clinical Trial With Vilobelimab In Cutaneous Squamous Cell Carcinoma
InflaRx N.V. (NASDAQ:IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced the start of the second dosing cohort of the
InflaRx Shares See Volume Spike As Traders Circulate Patent Doc From Canadian Gov’t. On Co.’s ‘ANTI-C5A BINDING MOIETIES WITH HIGH BLOCKING ACTIVITY’
https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/2780520/summary.html
InflaRx’s Vilobelimab Shows Encouraging Action Against Rare Autoimmune Disorder
InflaRx N.V. (NASDAQ:IFRX) has announced data from the European Phase II IXCHANGE study of vilobelimab in patients with ANCA-associated vasculitis (AAV). …
70 Biggest Movers From Friday
Gainers
Everspin Technologies, Inc. (NASDAQ: MRAM) shares surged 63.2% to close at $10.74 on Friday after the company reported better-than-expected Q3 results and issued Q4 sales guidance above estimates.
Raymond James Maintains Strong Buy on InflaRx, Raises Price Target to $15
Raymond James analyst Steven Seedhouse maintains InflaRx (NASDAQ:IFRX) with a Strong Buy and raises the price target from $14 to $15.
InflaRx Q3 EPS $(0.27) Up From $(0.29) YoY
InflaRx (NASDAQ:IFRX) reported quarterly losses of $(0.27) per share. This is a 6.9 percent increase over losses of $(0.29) per share from the same period last year.
Mid-Afternoon Market Update: Dow Surges 160 Points; Wolfspeed Shares Gain After Q1 Results
Toward the end of trading Thursday, the Dow traded up 0.45% to 35,651.09 while the NASDAQ rose 1.21% to 15,420.51. The S&P also rose, gaining 0.83% to 4,589.40.